KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.
"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."
Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.
"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."
Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.
Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 2008.
For more information, log on to http://www.pvct.com.
|SOURCE Provectus Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved